Thermalin Inc develops new forms of insulin that aims to lower the burder of insulin use, increase patient adoption of and adherence to insulin therapy, improve patient lives and outcomes, and lowe the cost of caring for individuals with diabetes. The company has reformulated the insulin molecule to enable new delivery devices and systems. Some of the technologies the company is developing include Ultra Rapid insulin, insulin that does not require refrigeration, concentrated miniaturized pumps, an insulin patch, an oral solution, and glucose-responsive solutions.
